Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

October 1^st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.

1mg REXULTI TABLET, Schizophrenia, Intas Pharmaceuticals

Rexulti (Brexpiprazole) - PSYCH-MENTAL HEALTH HUB

For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole - Kikuchi - 2021 - Neuropsychopharmacology Reports - Wiley Online Library

ex9901_img001.jpg

Table 2 from Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.

Brexpiprazole: A Newly Approved Atypical Antipsychotic Agent

Investigation Questions Drug's Approval for Agitation in AD

Rexulti.PDF

Rexulti (Brexpiprazole) - PSYCH-MENTAL HEALTH HUB

Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC

PDF] Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.

Brexpiprazole - Mechanism of Action and Clinical Application